Search Bar & Filters
Found 100 Actively Recruiting clinical trials
Actively Recruiting
Researchers are conducting a long-term observational study to understand the natural history, symptoms, and progression of fucosidosis, a rare disease without any approved treatments. This study aims to collect detailed information from individuals diagnosed with fucosidosis to better characterize the disease and inform future research and treatment development. The study is sponsored by JCR Pharmaceuticals Co., Ltd. and includes both retrospective and prospective components. The study has two parts Part A involves collecting past medical data from up to 57 participants, while Part B includes ongoing prospective data collection from up to 31 participants, many of whom may have participated in Part A. No experimental treatments are given participants receive only their usual medical care during the study. Participants will be observed over time to evaluate disease progression, with data collected from medical records and regular follow-up visits. The primary goal is to assess how fucosidosis develops in untreated individuals over up to four years. Information collected includes symptoms, treatment history, and clinical assessments to help researchers understand the disease course and support future study design. Participation may last several years depending on individual involvement in prospective data collection.
Actively Recruiting
Relapsed neuroblastoma is a common and serious childhood cancer that is difficult to treat, especially in high-risk cases where the disease returns after initial treatment or does not respond to standard therapies. This trial aims to improve survival for children aged 1 year and older with relapsed neuroblastoma by testing new combinations of treatments. It is an international, open-label, randomized phase III study designed to develop and evaluate these new therapies while also studying the biology of the disease using biomarker samples. Participants will be randomly assigned to one of two main treatment groups or enrolled in smaller dose confirmation groups testing new drug combinations. The current main treatments include combinations of dinutuximab beta, irinotecan, temozolomide, and bevacizumab given in 12 cycles every three weeks. Additional experimental groups may receive different combinations of these drugs. The trial includes a translational sub-study collecting tumor, blood, and bone marrow samples to better understand neuroblastoma and improve targeted therapies. During the study, patients will receive their assigned treatments over multiple cycles and be closely monitored for safety, treatment response, and quality of life. Researchers will perform various assessments including imaging scans, laboratory tests, and questionnaires to measure progression-free survival, side effects, and overall clinical benefit. Follow-up will continue up to five years after treatment to assess long-term outcomes and collect further data on patient health and disease progression.
Actively Recruiting
Researchers are studying kidney cachexia, a condition causing severe muscle loss, weakness, fatigue, poor appetite, and reduced quality of life in patients with kidney failure who are undergoing haemodialysis. This study evaluates whether a combined treatment approach, including exercise, dietary advice, and anti-inflammatory supplements, can improve outcomes compared to routine kidney care alone. The study focuses on patients at risk of kidney cachexia, aiming to assess the practicality and potential benefits of this integrated intervention in the healthcare system. Participants in the treatment group will receive a personalized exercise program involving aerobic and resistance training, dietary advice through one-on-one dietetic assessments and food diaries, and daily omega-3 oral supplements for 12 weeks. Weekly phone contacts will support adherence. The control group will continue with routine care without these additional interventions. The study uses a randomized, parallel design across multiple renal departments. During the 12-week study, participants will be monitored for recruitment success, physical function, muscle mass, body weight, quality of life, and survival. Data collection includes exercise diaries, dietary records, and interviews with patients and clinicians after treatment to identify improvements to the intervention. Researchers will evaluate how well the combined treatment works and its feasibility, with a focus on patient engagement and clinical outcomes related to kidney cachexia.
Actively Recruiting
Researchers are conducting an observational study to understand the short-term progression of geographic atrophy GA caused by age-related macular degeneration AMD in adults aged 55 and older. The goal is to identify participants with progressive GA and measure structural and functional changes, while exploring possible links to genetic and lifestyle factors. Participants will not receive any investigational treatments during this non-interventional study. Instead, their condition will be closely monitored over time using imaging techniques such as fundus autofluorescence FAF and optical coherence tomography OCT. The study will include assessments at baseline, month 3, and month 6 to track GA progression and related changes. Throughout the study, participants will undergo various eye examinations including visual acuity tests and microperimetry to measure retinal sensitivity. Researchers will collect data on GA progression and analyze correlations with genetic and lifestyle aspects. The study aims to provide detailed insight into GA changes over six months, with safety and adherence monitored by the research team. Participation will last approximately six months with scheduled visits for assessments.
Actively Recruiting
Researchers are evaluating the inhalation suspension of ensifentrine, given twice daily via a standard jet nebulizer, for its effects on people with non-cystic fibrosis bronchiectasis NCFBE. This randomized, double-blind, placebo-controlled Phase II study aims to assess the safety and efficacy of ensifentrine compared to placebo over up to 52 weeks. The main focus is to see how ensifentrine affects lung flare-ups, symptoms, and quality of life in participants who continue their standard care. Participants will be randomly assigned to receive either 3 mg of nebulized ensifentrine or a matching placebo, both administered twice daily through a jet nebulizer for up to 52 weeks. Neither participants nor study staff will know which treatment is given. Some participants may finish earlier if the study ends after the last participant completes the 24-week visit. This trial compares the study drug to placebo while all participants receive their usual care. During the study, participants will be monitored regularly with lung function tests, symptom questionnaires, and quality of life assessments at baseline and at several points up to 24 weeks and through study completion. Researchers will measure the rate of lung exacerbations and track adverse events for up to 52 weeks. Additional pharmacokinetic tests will be done in a sub-study. Participants will be expected to perform spirometry and provide sputum samples, and their medication adherence and safety will be closely followed throughout the study period.
Actively Recruiting
Healthy Volunteer
This research aims to pilot and evaluate an online compassion-based program designed to support the mental health of healthcare staff accessing psychological assessment within an Occupational Health Service. It compares this program with the usual treatment offered, which is Staffcare counselling. The study focuses on reducing burnout and stress by fostering self-compassion through Compassion Focused Therapy CFT and Compassionate Mind Training CMT. Participants are randomly assigned to one of two groups the Compassionate Mind Training CMT intervention or Treatment As Usual TAU. The CMT group receives a four-week online program led by a CMT expert, including weekly 30-minute videos, audio exercises, and reading materials to complete at their own pace. The TAU group receives standard care through Staffcare counselling, which involves six weekly counselling sessions via the Employee Assistance Programme. Participants complete online questionnaires at four points before treatment, mid-treatment, after treatment, and one month later. These assessments measure mental health, burnout, self-compassion, fear of self-compassion, and treatment credibility. Data is collected securely online. The study will monitor participant wellbeing and provide support as needed. Participation lasts through the intervention and follow-up periods, with confidentiality and anonymity maintained throughout.
Actively Recruiting
Researchers are evaluating new DNA damage repair inhibitors DDRis combined with radiotherapy for patients with stage IIB to IIIB non-small cell lung cancer NSCLC in this Phase IB study. The purpose is to find the recommended dose and safety of DDRis given with a fixed dose of curative radiotherapy, followed by up to 12 months of consolidation durvalumab immunotherapy in some groups. The study uses a specialized method to monitor dose-limiting toxicities over 13.5 months to guide safe dosing decisions. Participants receive radiotherapy administered in 30 daily fractions of 2Gy each, totaling 60Gy Monday to Friday. Some groups also receive oral DDRi drugs such as Olaparib, AZD1390, Ceralasertib, or AZD5305 alongside radiotherapy. Selected groups receive up to 12 months of durvalumab immunotherapy after radiotherapy. No placebo is used both patients and doctors know the assigned treatments. One study arm was discontinued. During the study, patients are closely followed to monitor side effects, cancer response, and treatment compliance. Blood samples are collected to track progress and explore which patients may benefit most. Researchers assess dose-limiting toxicities up to 13.5 months after radiotherapy start and evaluate safety, response, disease control, survival, and quality of life up to two years post-treatment. Participation lasts through treatment and follow-up periods for comprehensive monitoring.
Actively Recruiting
Researchers are studying the impact and burden of three skin conditions moderate or severe alopecia areata, non-segmental vitiligo, and moderate to severe hidradenitis suppurativa. The study includes adolescents and adults and aims to understand how these conditions affect quality of life and daily functioning in a large global population. This is an observational study where participants with each condition will have a single visit for data collection following routine clinical practice. No experimental treatments are given instead, the study gathers information during this one visit to assess disease characteristics and impact. During the visit, participants will complete questionnaires and clinical assessments specific to their condition. These include tools measuring symptom impact, hair loss severity, skin depigmentation, and quality of life related to each disease. This helps researchers better understand the real-world burden of these conditions. Participation involves only this one visit, with no long-term follow-up or additional procedures.
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
Researchers are evaluating the efficacy and safety of ifinatamab deruxtecan I-DXd in adults with unresectable advanced or metastatic esophageal squamous cell carcinoma ESCC who have experienced disease progression after treatment with platinum-based chemotherapy and immune checkpoint inhibitors. This phase 3 clinical trial compares I-DXd to the investigators choice of chemotherapy in this patient group to assess overall survival benefits. Participants are randomly assigned to receive either intravenous infusions of I-DXd at 12 mgkg every 21 days or investigator-selected chemotherapy drugs such as docetaxel, paclitaxel, or irinotecan hydrochloride. Treatment cycles repeat every three weeks, continuing until disease progression or other study endpoints. The study will measure overall survival, progression-free survival, objective response rate, duration of response, disease control rate, quality of life changes, safety events, and pharmacokinetic parameters for up to approximately 54 months. Throughout the study, participants will undergo regular assessments including imaging scans to measure tumor lesions, quality of life questionnaires, and safety monitoring for adverse events. Blood samples will be collected to analyze drug levels and immune responses. The studys main outcome is overall survival from randomization to death from any cause. Participants health and response to treatment will be followed closely during and after treatment for up to 54 months, with continued monitoring of safety and effectiveness measures.
1-10 of 100
1